Compare Amgen, Inc. (AMGN) vs Emerson Electric Co. (EMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Emerson Electric Co. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Emerson Electric Co. trades at $138 (market cap $77.79B). The key difference: Amgen, Inc. is far larger — about 2.5× Emerson Electric Co.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | EMR | |
|---|---|---|
Market Cap | $196.12B | $77.79B |
Sector | Health | Industrials |
52-Week High | $388.16 | $161.69 |
52-Week Low | $271.18 | $123.30 |
Enterprise Value | $241.41B | $90.05B |
Dividend Yield | 2.77% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Emerson Electric (EMR) trades at $138.88, up 0.78% today, with a bearish technical signal from moving averages. The stock shows stable revenue growth, with 2025 revenue of $18.02B and net income of $2.29B, supported by a strong gross profit margin of 52.67%. Recent news highlights investor attention and collaboration with Aramco on corrosion R&D, while the Intelligent Devices segment gains momentum.
EMR presents a mixed outlook: analyst consensus is bullish with a $157.60 price target, but technical indicators suggest near-term pressure. Key risks include volatile cash flows and competitive pressures in manufacturing electronics. The stock's valuation at a P/E of 32.15 may limit upside unless earnings accelerate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
